FDA Clearance Tracker · P110021
EDWARDS SAPIEN TRANSCATHETER HEART VALVE AND ACCESSORIES
Last checked: Nov 20, 2026Latest source record: Oct 19, 2012 (this decision)Source: openFDAMethods & limitations
Decided
Oct 19, 2012
Approval withdrawn
Time to decision
536 days
Received May 2, 2011. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P110021
- Device name
- EDWARDS SAPIEN TRANSCATHETER HEART VALVE AND ACCESSORIES
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- May 2, 2011
- Decided
- Oct 19, 2012
- Decision
- Approval withdrawn
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Supplements
- 51 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR EDWARDS SAPIEN¿ TRANSCATHETER HEART VALVE MODEL 9000TFX, SIZES 23MM AND 26MM, AND TRANSAPICAL AND TRANSFEMORAL ACCESSORIES LISTED ABOVE. THIS DEVICE IS INDICATED FOR THE FOLLOWING:TRANSAPICAL - THE EDWARDS SAPIEN TRANSCATHETER HEART VALVE, MODEL 9000TFX, SIZES 23 MM AND 26 MM, IS INDICATED FOR TRANSAPICAL DELIVERY IN PATIENTS WITH SEVERE SYMPTOMATIC CALCIFIED NATIVE AORTIC VALVESTENOSIS WITHOUT SEVERE AORTIC INSUFFICIENCY AND WITH EJECTION FRACTION >= 20% WHO HAVE BEEN EXAMINED BY A HEART TEAM INCLUDING AN EXPERIENCED CARDIAC SURGEON AND A CARDIOLOGIST AND FOUND TO BE OPERATIVE CANDIDATES FOR AORTIC VALVE REPLACEMENT BUT WHO HAVE A SOCIETY OF THORACIC SURGEONS OPERATIVE RISK SCORE >= 8% OR ARE JUDGED BY THE HEART TEAM TO BE AT A >=15% RISK OF MORTALITY FOR SURGICAL AORTIC VALVE REPLACEMENT. THE ASCENDRA BALLOON CATHETER IS INDICATED FOR THE TRANSAPICAL DELIVERY OF THE EDWARDS SAPIEN TRANSCATHETER HEART VALVE. TRANSFEMORALTHE EDWARDS SAPIEN TRANSCATHETER HEART VALVE, MODEL 9000TFX, SIZES 23 MM AND 26 MM, ISINDICATED FOR TRANSFEMORAL DELIVERY IN PATIENTS WITH SEVERE SYMPTOMATIC CALCIFIED NATIVE AORTIC VALVESTENOSIS WITHOUT SEVERE AORTIC INSUFFICIENCY AND WITH EJECTION FRACTION >20% WHO HAVE BEENEXAMINED BY A HEART TEAM INCLUDING AN EXPERIENCED CARDIAC SURGEON AND A CARDIOLOGIST AND FOUND TOEITHER BE: 1) INOPERABLE AND IN WHOM EXISTING CO-MORBIDITIES WOULD NOT PRECLUDE THE EXPECTEDBENEFIT FROM CORRECTION OF THE AORTIC STENOSIS; OR 2) BE OPERATIVE CANDIDATES FOR AORTIC VALVE REPLACEMENT BUT WHO HAVE A SOCIETY OF THORACIC SURGEONS PREDICTED OPERATIVE RISK SCORE > 8% OR ARE JUDGED BY THE HEART TEAM TO BE AT A >15% RISK OF MORTALITY FOR SURGICAL AORTIC VALVE REPLACEMENT.THE RETROFLEX 3 DELIVERY SYSTEM IS INDICATED FOR THE TRANSFEMORAL DELIVERY OF THE EDWARDSSAPIEN TRANSCATHETER HEART VALVE.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NPT. The earliest in FDA's data is P100041, decided Nov 2, 2011.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.